Immunity in Malignant Disease [Abridged] Professor P Alexander (Chester Beatty Research Institute, London) Immunotherapy of Cancer -Experience with Primary Sarcoma in the Rat
Starting from the experiments of Peter Gorer, evidence accumulating over the last ten years shows that tumours which arise in experimental animals as a result of exposure to carcinogenschemical, physical or viral -contain certain components in their plasma membrane which differ from those present in normal cells. The existence of such substances was revealed by techniques involving transplantation within pure-line animals (i.e. colonies in which all members are genetically identical and will accept skin grafts from one another). These tumour-specific antigens are difficult to detect by normal serological techniques and are identified by causing a host reactionpredominantly cell mediated -which is selectively cytotoxic to the tumour cells and not to the host cells. The realization that autochthonous tumours are, to some extent, foreign to the host in which they arise has given a great impetus to the search for immunological procedures that may be useful in the treatment of cancer. Several approaches have so far been investigated (see World Health Organization 1966) and the choice of method depends to a considerable extent on the nature of the host resistance to the tumour. In experimental animals the following situations have been encountered:
(1) The host has become tolerant to the tumourspecific antigens; this is the case in the so called 'spontaneous' murine mammary carcinomas and leukxmias which are caused by a virus vertically transmitted from the parent.
(2) The tumour cells are protected by circulating antibody which absorbs on to the cells without killing them, and prevents interaction with lymphocytes that are cytotoxic.
(3) The host is capable of reacting but does not do so to its full extent because the tumour-specific antigens do not present in the most immunogenic form.
(4) The host reacts fully but the rate of production of new tumour cells is greater than the host's capacity to destroy them .
The tumour system which we have studied (Haddow & Alexander 1964 , Delorme & Alexander 1964 , Alexander, Delorme & Hall 1966 , Alexander et al. 1967 ) falls into the last category; sarcomas were induced in rats by the subcutaneous implantation of a pellet of the carcinogen 3:4 benzpyrene. Studies were begun when the tumours had attained a size of 1-5 cm in diameter; without treatment these tumours grow relentlessly and kill within a few weeks; they are very refractory to radio-or chemo-therapy and almost inevitably recur after surgery. Spontaneous regression has never been encountered, yet a variety of techniques (Alexander et al. 1967 ) have demonstrated the existence of a reaction of the host directed against the autochthonous tumour, that presumably slowed down the rate of growth but was not capable of arresting development. Our approach to immunotherapy was to attempt to augment the host's own reaction in the hope that the defence reaction would not then be overwhelmed. 'Vaccination' with pieces of the tumour that had been rendered nonviable by exposure to X-rays (i.e. injection of irradiated autografts) was of some benefit when combined with localized radiotherapy but was ineffective by itself (Haddow & Alexander 1964 . In this procedure no attempt was made (e.g. by pretreatment with cytotoxic agents) to make it possible for the injected lymphocytes to colonize the lymphoid organs of the tumour-bearing rats. In our experiments the injected cells did not form a graft and no sign of a 'graft-versus-host' reaction was encountered. As a result of this treatment the primary tumours usually regressed -though in the majority of cases they recurred -but only if the lymphocytes were obtained from donors immunized with the particular tumour to be treated. Non-immune lymphocytes, or lymphocytes from animals immunized with another tumour, were completely ineffective. Since the antigens in chemically induced tumours are known to be different for each tumour and not to cross-react this supports the hypothesis that the antitumour effect achieved by the injection of the immune lymphocyte is due to an immunological attack directed against the tumour-specific antigens.
The mechanism of action is not, however, a direct interaction of the injected lymphocyte with the tumour cells resulting in destruction of the latter.1 They do not reach the tumour but settle mainly in the lymphoid organs and predominantly in the spleen. A number of experiments. (Alexander, Delorme & Hall 1966) indicate that the lymphocytes serve to initiate a process which is taken to completion by the host itself. There are several different populations of lymphocytes involved in the various stages of the immune response and it seems unlikely that those responsible for the antitumour effect are those that are directly cytotoxic. The effective cells are probably the large pyroninophilic blast cells that begin to leave a node within three to four days after antigenic stimulation (Alexander, Delorme & Hall 1966) .
In view of the indication that the action of the injected lymphocytes was indirect and might not require prolonged survival of the injected cells, heterologous donors were tried. Lymphocytes obtained from the efferent lymphatic duct of a node in a sheep stimulated with rat tumour proved equally effective. As in the homologous system their action was highly specific and confined solely to that primary tumour which had been used for immunization (Alexander, Delorme & Hall 1966 ). The next step was to test whether the intact cells were necessary for the antitumour reaction or whether a particular cell component given alone might produce the same reaction. There wete 'This is not to say that lymphocytes cannot act directly, for ascites tumours can be destroyed by such a mechanism (cf. Alexander, Connell & Mikulska 1966) many reasons for suspecting that the RNA in the large lymphocyte might be responsible and indeed this material proved to be growth inhibitory (Alexander et al. 1967) . Like the intact cells the RNA from either rat or sheep lymphocytes was quite tumour specific and only acted against that tumour with which the donor animals had been immunized. Unlike the cells, the RNA was not active if given intravenously and in all our experiments was injected into the foot-pad so that it should have a very short period of travel before reaching a node. In this way destruction by the ubiquitous enzyme RNAase would be minimized.
Although the detailed mechanism of action of these procedures remains to be elucidated, all our experiments indicate that the host's own capacity to respond to the tumour is thereby increased.
In considering possible practical applications it is important to bear in mind that the primary tumours used in these experiments are highly antigenic and that they are actively opposed by the host. A relatively small increase in the host resistance may therefore be all that is needed to tilt the balance against the tumour. Whether there is a human equivalent to these chemically induced rat tumours remains to be discovered. We do not know if immune lymphocytes (or their RNA) are likely to be effective if there is not a pre-existing host response against the tumour-specific antigens. Finally, it must be emphasized that even in the case of these rat tumours immunotherapy is without effect if the tumour mass is too large (Delorme & Alexander 1964) . All the available evidence suggests that at best immunotherapy can only be an adjuvant which eliminates residual disease after other forms of treatment -notably surgery -have removed the bulk of the malignant tissues.
